Abstract
The repair of cutaneous wounds in the postnatal animal is associated with the development of scar tissue. Directing cell activities to efficiently heal wounds while minimizing the development of scar tissue is a major goal of wound management and the focus of intensive research efforts. Type III collagen (Col3), expressed in early granulation tissue, has been proposed to play a prominent role in cutaneous wound repair, although little is known about its role in this process. To establish the role of Col3 in cutaneous wound repair, we examined the healing of excisional wounds in a previously described murine model of Col3 deficiency. Col3 deficiency (Col3+/–) in aged mice resulted in accelerated wound closure with increased wound contraction. In addition, Col3-deficient mice had increased myofibroblast density in the wound granulation tissue as evidenced by an increased expression of the myofibroblast marker, α-smooth muscle actin. In vitro, dermal fibroblasts obtained from Col3-deficient embryos (Col3+/– and –/–) were more efficient at collagen gel contraction and also displayed increased myofibroblast differentiation compared to those harvested from wild-type (Col3+/+) embryos. Finally, wounds from Col3-deficient mice also had significantly more scar tissue area on day 21 postwounding compared to wild-type mice. The effect of Col3 expression on myofibroblast differentiation and scar formation in this model suggests a previously undefined role for this ECM protein in tissue regeneration and repair.
References
1.
Arora, P.D., C.A. McCulloch (1994) Dependence of collagen remodelling on alpha-smooth muscle actin expression by fibroblasts. J Cell Physiol 159: 161–175.
2.
Badillo, A.T., R.A. Redden, L. Zhang, E.J. Doolin, K.W. Liechty (2007) Treatment of diabetic wounds with fetal murine mesenchymal stromal cells enhances wound closure. Cell Tissue Res 329: 301–311.
3.
Burk, C.J., C. Aber, E.A. Connelly (2006) Ehlers-Danlos syndrome type IV: keloidal plaques of the lower extemities, amniotic band limb deformity and a new mutation. J Am Acad Dermatol 56: S53–S54.
4.
Byers, P.H., K.A. Holbrook, B. McGillivray, P.M. MacLeod, R.B. Lowry (1979) Clinical and ultrastructural heterogeneity of type IV Ehlers-Danlos syndrome. Hum Genet 47: 141–150.
5.
Cass, D.L., K.G. Sylvester, E.Y. Yang, T.M. Crombleholme, N.S. Adzick (1997) Myofibroblast persistence in fetal sheep wounds is associated with scar formation. J Pediatr Surg 32: 1017–1021.
6.
Cook, H., K.J. Davies, K.G. Harding, D.W. Thomas (2000) Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2, and MMP-2 activity. J Invest Dermatol 115: 225–233.
7.
Cooper, T.K., Q. Zhong, M. Krawczyk, H.J. Tae, G.A. Müller, R. Schubert, L.A. Myers, H.C. Dietz, M.I. Talan, W. Briest (2010) The haploinsufficient Col3a1 mouse as a model for vascular Ehlers-Danlos syndrome. Vet Pathol 47: 1028–1039.
8.
Cuttle, L., M. Nataatmadja, J.F. Fraser, M. Kempf, R.M. Kimble, M.T. Hayes (2005) Collagen in the scarless fetal skin wound: detection with Picrosirius-polarization. Wound Repair Regen 13: 198–204.
9.
Desmouliere, A., A. Geinoz, F. Gabbiani, G. Gabbiani (1993) Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in GT myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122: 103–111.
10.
Desmouliere, A., M. Redard, I. Darby, G. Gabbiani (1995) Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 146: 56–66.
11.
Ehrlich, H.P. (1988) The modulation of contraction of fibroblast populated collagen lattices by types I, II, and III collagen. Tissue Cell 20: 47–50.
12.
Gabbiani, G. (2003) The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200: 500–503.
13.
Germain, D.P. (2007) Ehlers-Danlos syndrome type IV. Orphanet J Rare Dis 2: 32–41.
14.
Goldberg, S.R., G.L. Quirk, V.W. Sykes, T. Kordula, D.A. Lanning (2007) Altered procollagen gene expression in mid-gestational mouse embryonic wounds. J Surg Res 143: 27–34.
15.
Grinnell, F., C.H. Ho, Y.C. Lin, G. Skuta (1999a) Differences in the regulation of fibroblast contraction of floating versus stressed collagen matrices. J Biol Chem 2: 918–923.
16.
Grinnell, F., M. Zhu, M.A. Carlson, J.M. Abrams (1999b) Release of mechanical tension triggers apoptosis of human fibroblasts in a model of regressing granulation tissue. Exp Cell Res 248: 608–619.
17.
Hinz, B., G. Celetta, J.J. Tomasek, G. Gabbiani, C. Chaponnier (2001) Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell 12: 2730–2741.
18.
Hinz, B., G. Gabbiani (2003) Mechanisms of force generation and transmission by myofibroblasts. Curr Opin Biotechnol 14: 546.
19.
Hurme, T., H. Kalimo, M. Sandberg, J.M. Lehto, E. Vuorio (1991) Localization of type I and III collagen and fibronectin production in injured gastrocnemius muscle. Lab Invest 64: 76–84.
20.
Järveläinen, H., P. Puolakkainen, S. Pakkanen, E.L. Brown, M. Höök, R.V. Iozzo, E.H. Sage, T.N. Wight (2006) A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen 14: 443–452.
21.
Kyriakides, T.R., P. Bornstein (2003) Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90: 986–992.
22.
Lee, T.Y., G.S. Chin, W.J. Kim, D. Chau, G.K. Gittes, M.T. Longaker (1999) Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg 43: 179–184.
23.
Liao, H., J. Zakhaleva, W. Chen (2009) Cells and tissue interactions with glycated collagen and their relevance to delayed diabetic wound healing. Biomaterials 30: 1689–1696.
24.
Lin, R.Y., K.M. Sullivan, P.A. Argenta, M. Meuli, H.P. Lorenz, N.S. Adzick (1995) Exogenous transforming growth factor-beta amplifies its own expression and induces scar formation in a model of human fetal skin repair. Ann Surg 222: 146–154.
25.
Liu, S.H., R.S. Yang, R. Al-Haikh, J.M. Lane (1995) Collagen in tendon, ligament and bone healing: a current review. Clin Orthop Relat Res 318: 265–278.
26.
Liu, X., H. Wu, M. Burne, S. Krane, R. Jaenisch (1997) Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci USA 94: 1852–1856.
27.
Lygoe, K.A., I. Wall, P. Stephens, C. Li (2007) Role of vitronectin and fibronectin receptors in oral mucosal and dermal myofibroblast differentiation. Biol Cell 99: 601–614.
28.
McGrath, M.H., S.A. Hundahl (1982) The spatial and temporal quantification of myofibroblasts. Plast Reconstr Surg 69: 975–985.
29.
Merkel, J.R., B.R. DiPaolo, G.G. Hallock, D.C. Rice (1988) Type I and type III collagen content of healing wounds in fetal and adult rats. Proc Soc Exp Biol Med 187: 493–497.
30.
Mochitate, K., P. Pawelek, F. Grinnell (1991) Stress relaxation of contracted collagen gels: disruption of actin filament bundles, release of cell surface fibronectin, and down-regulation of DNA and protein synthesis. Exp Cell Res 193: 198–207.
31.
Neptune, E.R., P.A. Frischmeyer, D.E. Arking, L. Myers, T.E. Bunton, B. Gayraud, F. Ramirez, L.Y. Sakai, H.C. Dietz (2003) Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33: 407–411.
32.
Occleston, N.L., A.D. Metcalfe, A. Boanas, N.J. Burgoyne, K. Nield, S. O’Kane, M.W. Ferguson (2010) Therapeutic improvement in scarring: mechanisms of scarless and scar-forming healing and approaches to the discovery of new treatments. Derm Res Pract 2010, E-pub ahead of print.
33.
Oderich, G.S., J.M. Panneton, T.C. Bower, N.M. Lindor, K.J. Cherry, A.A. Noel, M. Kalra, T. Sullivan, J. Glowacki (2005) The spectrum, management and clinical outcome of Ehlers Danlos syndrome IV: a 30-year experience. J Vasc Surg 42: 98–106.
34.
Oganesian, A., S. Au, J.A. Horst, L.C. Holzhausen, A.J. Macy, J.M. Pace, P. Bornstein (2006) The NH2-terminal propeptide of type I procollagen acts intracellularly to modulate cell function. J Biol Chem 281: 38507–38518.
35.
Parizi, M., E.W. Howard, J.J. Tomasek (2000) Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase. Exp Cell Res 254: 210–220.
36.
Pepin, M., U. Schwarze, A. Superti-Furga, P.H. Byers (2000) Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular form. New Engl J Med 342: 673–680.
37.
Phillips, L.G., L. Seppinen, R. Sormunen, Y. Soini, H. Elamaa, R. Heljasvaara, T. Phihlajaniemi (2008) Lack of collagen XVIII accelerates cutaneous wound healing, while overexpression of its endostatin domain leads to delayed healing. Matrix Biol 27: 535–546.
38.
Powell, D.W., R.C. Mifflin, J.D. Valentich, S.E. Crowe, J.I. Saada, A.B. West (1999) Myofibroblasts: paracrine cells important in health and disease. Am J Physiol 277: C1–9.
39.
Reid, R.R., H.K. Said, J.E. Mogford, T.A. Mustoe (2004) The future of wound healing: pursuing surgical models in transgenic and knockout mice. J Am Coll Surg 199: 578–585.
40.
Romanic, A.M., E. Adachi, K.E. Kadler, Y. Hojima, D.J. Prockop (1991) Copolymerization of pN collagen III and collagen I: pN collagen III decreases the rate of incorporation of collagen I into fibrils, the amount of collagen I incorporated and the diameter of the fibrils formed. J Biol Chem 266: 12703–12709.
41.
Rungger-Brandle, E., G. Gabbiani (1983) The role of the cytoskeletal and cytocontractile elements in pathologic processes. Am J Pathol 110: 361–385.
42.
Schwarze, U., W.I. Schievink, E. Petty, M.R. Jaff, D. Babovic-Vuksanovic, K.J. Cherry, M. Pepin, P.H. Byers (2001) Haploinsufficiency for one Col3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV. Am J Hum Genet 69: 989–1001.
43.
Serini, G., G. Gabbiani (1999) Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 250: 273–283.
44.
Shah, M., D.M. Foreman, M.W. Ferguson (1995) Neutalisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 108: 985–1002.
45.
Sharma, N.L., V.K. Mahajan, N. Gupta, N. Ranjan, A. Lath (2009) Ehlers-Danlos syndrome-vascular type (ecchymotic variant): cutaneous and dermatopathologic features. J Cutan Pathol 36: 486–492.
46.
Stevenson, K., U. Kucich, C. Whitbeck, R.M. Levin, P.S. Howard (2006) Functional changes in bladder tissue from type III collagen-deficient mice. Mol Cell Biochem 283: 107–114.
47.
Tomasek, J.J., C.J. Haaksma, R.J. Eddy, M.B. Vaughan (1992) Fibroblast contraction occurs on release of tension in attached collagen lattices: dependency on an organized actin cytoskeleton and serum. Anat Rec 232: 359–368.
48.
Vaughan, M.B., E.W. Howard, J.J. Tomasek (2000) Transforming growth factor-β1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res 257: 180–189.
49.
Volk, S.W., A. Radu, L. Zhang, K.W. Liechty (2007) Stromal progenitor cell therapy corrects the wound healing defect in the ischemic rabbit ear model of chronic wound repair. Wound Repair Regen 15: 736–747.
50.
Zhu, Y., A. Oganesian, D.R. Keene, L.J. Sandell (1999) Type IIA procollagen containing the cysteine-rich amino propeptide is deposited in the extracellular matrix of prechondrogenic tissue and binds to TGFβ1 and BMP2. J Cell Biol 144: 1069–1080.
51.
Zoppi, N., R. Gardella, A. DePaepe, S. Barlati, M. Colombi (2004) Human fibroblasts with mutations in COL5A1 and COL3A1 genes do not organize collagens and fibronectin in the extracellular matrix, down-regulate α2β1 integrin, and recruit αvβ3 instead of α5β1 integrin. J Biol Chem 279: 18157–18168.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
